The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment

Nasreddine, Ziad; Phillips, Natalie A.; Bédirian, Valérie; Charbonneau, Simon; Whitehead, Victor; Collin, Isabelle; Cummings, Jeffrey L.; Chertkow, Howard

doi:10.1111/j.1532-5415.2005.53221.x

Cited by 19,098 publications

(15,099 citation statements)

References 17 publications

Supporting

152

Mentioning

14,615

Contrasting

Unclassified

296

Order By: Relevance

“…The maximum score is 146 and scores below 130 indicate presence of visuospatial neglect. The Montreal Cognitive Assessment40 was used to screen cognition. The Montreal Cognitive Assessment is a screening tool for cognition and has a maximum score of 30, with scores below 25 indicating cognitive impairment.…”

Section: Methodsmentioning

confidence: 99%

Differential Impact of Acute Lesions Versus White Matter Hyperintensities on Stroke Recovery

Hawe

Findlater

Kenzie

et al. 2018

JAHA

View full text Add to dashboard Cite

BackgroundUnderstanding how the size of acute lesions and white matter hyperintensities (WMH) impact stroke recovery can improve our ability to predict outcomes and tailor treatments. The aim of this exploratory study was to investigate the role of acute lesion volume and WMH volume on longitudinal recovery of specific sensory, motor, and cognitive impairments after stroke using robotic and clinical measures.Methods and ResultsEighty‐two individuals were assessed at 1, 6, 12, and 26 weeks poststroke with robotic tasks and commonly used clinical measures. The volumes of acute lesions and WMH were measured on fluid‐attenuated inversion recovery images. Linear mixed models were used to investigate the role of acute lesions and WMH on parameters derived from the robotic tasks and clinical measures. Regression analysis determined the added value of acute lesion and WMH volumes along with measures of initial performance to predict outcomes at 6 months. Acute lesion volume has widespread effects on sensory, motor, and overall functional recovery poststroke. The impact of WMH was specific to cognitive impairments. Apart from the robotic position sense task, neither lesion volume nor WMH measure had significant ability to predict outcomes at 6 months over using initial impairment as measured by robotic assessments alone.ConclusionsWhile acute lesion volume and WMH may impact different impairments poststroke, their clinical utility in predicting outcomes at 6 months poststroke is limited.

show abstract

Section: Methodsmentioning

confidence: 99%

Differential Impact of Acute Lesions Versus White Matter Hyperintensities on Stroke Recovery

Hawe

Findlater

Kenzie

et al. 2018

JAHA

View full text Add to dashboard Cite

show abstract

“…While measures varied slightly between sites, all participants completed a study visit that included historical information on clinical features and treatment, neurological examination including quantitative motor measures utilizing the Unified Parkinson Disease Rating Scale (UPDRS,10) and MDS‐UPDRS11 Hoehn and Yahr rating scale,12 and disability from the Schwab‐England rating scale. Information on nonmotor PD features included measures of cognition (Montreal Cognitive Assessment, MoCA,13), mood (Geriatric Depression scale, abbreviated version GDS15,14 Beck Depression Inventory, BDI15), dysautonomia (SCOPA‐AUT,16), olfaction (UPSIT17), and sleep (Epworth Sleepiness Scale, ESS18 and REM sleep behavior disorder questionnaire, RBDSQ19). However, because of the large number of missing responses, the sexual questions were not analyzed in either group in the SCOPA‐AUT.…”

Section: Subjects/materials and Methodsmentioning

confidence: 99%

Sex differences in LRRK2 G2019S and idiopathic Parkinson's Disease

Luciano

Wang

Ortega

et al. 2017

Ann Clin Transl Neurol

View full text Add to dashboard Cite

ObjectiveTo evaluate sex differences and the relative effect of G2019S LRRK2 mutations in Parkinson's disease (PD).Methods530 LRRK2 PD carriers and 759 noncarrier PD (idiopathic, IPD) evaluated as part of the Fox Foundation (MJFF) Consortium were included. All participants completed a study visit including information on clinical features, treatment, examination, and motor and nonmotor questionnaires. Clinical features were compared between men and women separately for IPD and LRRK2 PD; and features were compared between IPD and LRRK2 PD separately for men and women.Results Among IPD: men had higher levodopa equivalency dose (LED), worse activities of daily living and motoric severity but lower complications of therapy (UPDRS‐IV). IPD women had higher olfaction and thermoregulatory scores and were more likely to report family history of PD. Among LRRK2 PD: Male predominance was not observed among G2019S LRRK2 cases. Women had worse UPDRS‐IV but better olfaction. Among same sex:LRRK2 men and women had better olfaction than IPD counterparts. LRRK2 men demonstrated lower motor and higher cognitive, RBD and thermoregulation scores than IPD men and LRRK2 women had greater UDPRS‐IV and rates of dyskinesia.InterpretationThere were clinical differences between sexes with a more severe phenotype in IPD men and more complications of therapy in women. The more severe male phenotype was moderated by LRRK2, with LRRK2 men and women showing less diversity of phenotype. Our study supports that both genetics and sex drive phenotype, and thus trials in LRRK2 and IPD should consider gender stratification in design or analysis.

show abstract

“…A selection of standardized tests assessing (1) global cognitive performance: Montreal Cognitive Assessment (MoCA)24; (2) learning and verbal memory: Hopkins Verbal Learning Test–Revised (HVLT‐R)25; (3) executive function: the Verbal Fluency Test26 and Trail Making Tests B27; (4) psychomotor speed: Trail Making Tests A27 and Symbol Digit Test28; (5) motor skills: the Hand Tapping Test29; (6) olfactory perception: the Olfactory Discrimination and Identification Test30; (7) affect: the Montgomery–Åsberg Depression Rating Scale (MADRS),31 the Beck Depression Inventory II (BDI‐II),32 and the Apathy Evaluation Scale33; and (8) impulsiveness: Barratt Impulsiveness Scale34 (Table 2). …”

Section: Methodsmentioning

confidence: 99%

Sleep deficits but no metabolic deficits in premanifest Huntington's disease

Lázár

Panin

Goodman

et al. 2015

Annals of Neurology

106

107

View full text Add to dashboard Cite

ObjectiveHuntington disease (HD) is a fatal autosomal dominant, neurodegenerative condition characterized by progressively worsening motor and nonmotor problems including cognitive and neuropsychiatric disturbances, along with sleep abnormalities and weight loss. However, it is not known whether sleep disturbances and metabolic abnormalities underlying the weight loss are present at a premanifest stage.MethodsWe performed a comprehensive sleep and metabolic study in 38 premanifest gene carrier individuals and 36 age‐ and sex‐matched controls. The study consisted of 2 weeks of actigraphy at home, 2 nights of polysomnography and multiple sleep latency tests in the laboratory, and body composition assessment using dual energy x‐ray absorptiometry scanning with energy expenditure measured over 10 days at home by doubly labeled water and for 36 hours in the laboratory by indirect calorimetry along with detailed cognitive and clinical assessments. We performed a principal component analyses across all measures within each studied domain.ResultsCompared to controls, premanifest gene carriers had more disrupted sleep, which was best characterized by a fragmented sleep profile. These abnormalities, as well as a theta power (4–7Hz) decrease in rapid eye movement sleep, were associated with disease burden score. Objectively measured sleep problems coincided with the development of cognitive, affective, and subtle motor deficits and were not associated with any metabolic alterations.InterpretationThe results show that among the earliest abnormalities in premanifest HD is sleep disturbances. This raises questions as to where the pathology in HD begins and also whether it could drive some of the early features and even possibly the pathology. Ann Neurol 2015;78:630–648

show abstract

The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment

Abstract: MCI as an entity is evolving and somewhat controversial. The MoCA is a brief cognitive screening tool with high sensitivity and specificity for detecting MCI as currently conceptualized in patients performing in the normal range on the MMSE.

Cited by 19,098 publications

References 17 publications

Differential Impact of Acute Lesions Versus White Matter Hyperintensities on Stroke Recovery

Differential Impact of Acute Lesions Versus White Matter Hyperintensities on Stroke Recovery

Sex differences in LRRK2 G2019S and idiopathic Parkinson's Disease

Sleep deficits but no metabolic deficits in premanifest Huntington's disease

Contact Info

Product

Resources

About